Orphazyme, a listed company in Denmark that has been restructuring since March, has postponed its annual report for 2021 yet again, a company press release states.
This follows the Sunday announcement that the Danish firm has come to a binding agreement with US-based Kempharm, entailing the sale of all substantial Orphazyme assets and business activities.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Genmab to submit cancer candidate epcoritamab to the FDA before year-end
The US Food and Drug Administration will receive a marketing authorization application from Genmab and partner Abbvie in the second half of this year.
Novo Nordisk denied general conditional reimbursement for Wegovy in Denmark – again
The Danish Medicines Agency has been told for the second time that the price of the obesity drug is not in line with the effect it provides.
Bavarian Nordic is working with EMA on monkeypox vaccine label expansion
Bavarian Nordic’s smallpox vaccine Imvanex has previously been used off-label to protect close contacts from monkeypox in several countries. The Danish vaccine firm is now working with the EMA to expand the label in an ”accelerated process.”
Coloplast's climate goals approved by international initiative
The Science Based Targets initiative has approved Coloplast’s carbon emission reduction goals.
Top news from MedWatch this week
Miss anything?
Antibody Engineering Scientist 
Principal Laboratory Technologist Medicinal Chemistry 
Scientific Writer 
Medical Advisor 
Team Manager for Pharmacovigilance 
KLIFO is looking for a Project Director for our office in Denmark or Germany or Sweden 
Regulatory Affairs Manager - Maternity Cover 
QA Senior Specialist 
Global Learning Specialist 
Project Managers keep all of us healthy